NuGEN Technologies Announces WT-Ovation™ FFPE System
Product News Apr 11, 2007
NuGEN Technologies, Inc. has announced a system designed to access the critical biological information contained within precious FFPE (formalin-fixed, paraffin-embedded) tissue samples collected and banked through years of clinical studies and cancer research.
The NuGEN claims that its WT-Ovation™ FFPE System is the first and only whole transcriptome amplification system that generates cDNA for analysis on Affymetrix GeneChip® microarrays and qPCR enabling global gene expression analysis on vast archives of small and degraded samples.
The WT-Ovation FFPE System can offer robust, sensitive, and reproducible linear amplification with as little as 50 nanograms of FFPE total RNA into micrograms of cDNA in a simple, easy-to-automate, six-hour process. This whole transcriptome amplification approach employs NuGEN’s Ribo-SPIA™ technology and provides both 3’-initiated and random-primed amplification designed for very small and significantly degraded samples.
The resulting amplified cDNA may be analyzed using qPCR, or it can be fragmented and labeled using NuGEN’s FL-Ovation™ cDNA Biotin Module V2 for hybridization to GeneChip microarrays in the same day. This WT-Ovation FFPE System can also be used for ultra-low RNA input amplifications in the low picogram range, using more intact RNA from sources other than FFPE.
Sue Pandey, NuGEN vice president of commercial operations explained, “Expression analysis of FFPE-derived RNA samples has long been a challenge for researchers and clinicians due to the marked sample degradation and modifications caused by long-term storage and fixation methods. Now, investigators have access to a solution that enables these valuable samples to be effectively used in clinical research.”
To date, institutions around the globe have archived countless FFPE samples in hopes that one day researchers would be able to study them individually and in aggregate to understand how genes are expressed in response to diseases, events, and treatments. These specimens, often collected before and after clinical trials, are of significant value in today’s discovery efforts because of the in-depth prospective clinical records associated with them.
“This is an important step forward for pharmacogenomics and personalized medicine,” noted Garry Miyada, NuGEN vice president of product development.
“Unlocking the treasure trove of information in long-held FFPE samples can advance the development of more effective treatments for a broad range of cancers. With this system, it is now possible to implement archiving strategies allowing the more stable cDNA to be stored and studied frequently, while large portions of the original FFPE RNA may be saved for future investigation.”
As a result, the WT-Ovation FFPE System is particularly valuable for consortia with FFPE samples from studies conducted in numerous locations around the globe. Until now, such groups have found it challenging to share irreplaceable samples. The NuGEN system makes it possible to yield and store large volumes of cDNA that can then be shared and analyzed by various laboratories and research centers.